PCSK9 inhibitors

Patients who need PCSK9 inhibitors can’t get themStudy: PCSK9 inhibitors are being rejected by insurers at very high rates even in high-risk patients like those with familial hypercholesterolemia.
Game-changing cholesterol-buster further reduces heart attack, strokeA new outcomes study shows that the PCSK9 inhibitor Repatha significantly reduced the risk of hard major adverse cardiovascular events in high-risk patients by 20%.
PCSK9 Inhibitors: The First of Their KindThe first of their kind, evolocumab and alirocumab belong to a new class of cholesterol lowering agents.
Four innovative models rein in pharma costs
Four innovative models rein in pharma costsPlans and PBMs are finding new ways to rein in pharmacy costs.
Study: New cholesterol drugs cost 356 times more than genericsA report from the Alliance of Community Health Plans can help get a better sense of how well drugs help patients compared to other treatment options.
Are PCSK9 inhibitors too pricey?
Are PCSK9 inhibitors too pricey?PCSK9 inhibitors such as alirocumab (Praluent, Sanofi) and evolocumab (Repatha, Amgen) are priced too high to benefit the US healthcare system, according to a new study.
Cardiovascular drugs: Current spending, future outlookCardiovascular drugs are among the most widely used, since their indications are far reaching and address conditions that are prevalent among a large population.
PCSK9 inhibitor benefits patients with statin intolerancePCSK9 inhibitor benefits patients with statin intolerance
Best candidates for PCSK9 inhibitors
Best candidates for PCSK9 inhibitorsPBMs, insurers use cautious approach when managing these cholesterol-lowering drugs.
Top ways you can impact drug spendingHow at-risk negotiations with pharmaceutical manufacturers and medication adherence programs improve both sides of the healthcare value equation: patient outcomes and costs.